Capmatinib hydrochloride(free base)
CAS No. 1029714-89-3
Capmatinib hydrochloride(free base)( INC280 | INCB28060 )
Catalog No. M21656 CAS No. 1029714-89-3
Capmatinib hydrochloride is a potent orally active selective and ATP competitive c-Met kinase inhibitor?potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 45 | Get Quote |
|
| 5MG | 64 | Get Quote |
|
| 10MG | 96 | Get Quote |
|
| 25MG | 172 | Get Quote |
|
| 50MG | 259 | Get Quote |
|
| 100MG | 389 | Get Quote |
|
| 500MG | 888 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCapmatinib hydrochloride(free base)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCapmatinib hydrochloride is a potent orally active selective and ATP competitive c-Met kinase inhibitor?potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).
-
DescriptionCapmatinib hydrochloride is a potent orally active selective and ATP competitive c-Met kinase inhibitor?potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).
-
In VitroCapmatinib (INCB28060) inhibits c-MET phosphorylation with an IC50 value of approximately 1 nM and a concentration of approximately 4 nM inhibits c-MET more than 90%, which isreversible and the effect is significantly reduced in several hours after the compound is removed and completely disappeared by 48 hours.Capmatinib (INCB28060) (0-10000 nM; 72 h) inhibits the proliferation of SNU-5, S114, H441 and U-87MG.Capmatinib (INCB28060) (0.06-62.25 nM; 2h) effectively inhibits phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5.Capmatinib (INCB28060) (0.24-63 nM; over night) prevents HGF-stimulated H441 cell migration.Capmatinib (INCB28060) (0.5-50 nM; 20 min) suppresses phosphorylation of both EGFR and HER-3 rapidly.Capmatinib (INCB28060) (0-333 nM; 24 h) induces apoptosis in SNU-5 cells. Cell Viability Assay Cell Line:SNU-5, S114, H441 and U-87MG Concentration:0-10000 nM Incubation Time:72 h Result:Inhibited the cell viability of SNU-5 and S114, as well as the colony formation of H441 and U-87MG, with IC50 values of 1.2 nM, 12.4 nM, ~0.5 nM and 2 nM, respectively.Cell Migration Assay Cell Line:H441 (stimulated with 50 ng/mL recombinant human HGF for 24h)Concentration:0.24, 1, 4, 16 and 63 nMIncubation Time:Over nightResult:Prevented HGF-stimulated H441 cell migration, with IC50 of approximately 2 nM, and less cell migration at 16 nM.Western Blot Analysis Cell Line:SNU-5 Concentration:0.06, 0.24, 0.98, 3.91, 15.63 and 62.25 nM Incubation Time:2 h Result:Effectively inhibited phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5.Western Blot Analysis Cell Line:H1993 cells Concentration:0.5, 5 and 50 nM Incubation Time:20 min Result:Suppressed phosphorylation of both EGFR and HER-3 rapidly and as effectively as the compound inhibited c-MET phosphorylation in H1993 cells.Apoptosis Analysis Cell Line:SNU-5 cellsConcentration:0.017, 0.15, 1.37, 12.33, 111 and 333 nM Incubation Time:24 h Result:Effectively induced DNA fragmentation.
-
In VivoCapmatinib (INCB28060) (1-30 mg/kg; PO, twice daily, for 2 weeks) exhibits dose-dependent inhibition of tumor growth, and shows well tolerance at all doses during the treatment periods, with no evidence of overt toxicity or weight loss in U-87MG tumor mice model.Capmatinib (INCB28060) (0.03-10 mg/kg; PO, single dosage) causes inhibition of c-MET phosphorylation in S114 tumor mice model. Animal Model:Female Balb/c nu/nu mice (inoculated subcutaneously with 5×106 U-87MG glioblastoma cells)Dosage:1, 3, 10 and 30 mg/kg Administration:PO, twice daily, for 2 weeks Result:Exhibited dose-dependent inhibition of tumor growth with 35% and 76% at 1 and 3 mg/kg once daily; resulted in partial regressions in 6 of 10 U-87MG tumor-bearing mice at 10 mg/kg once daily; and showed well tolerance at all doses during the treatment periods, with no evidence of overt toxicity or weight loss. Animal Model:Female Balb/c nu/nu mice (inoculated subcutaneously with 4×106 S114 tumor cells) Dosage:0.03, 0.1, 0.3, 1, 3 and 10 mg/kg Administration:PO, single dosage Result:Caused approximately 50% and 90% inhibition of c-MET phosphorylation at 0.03 and 0.3 mg/kg after administration of 30 min, and inhibition of phospho-c-MET exceeded 90% after 7 hours.
-
SynonymsINC280 | INCB28060
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met
-
Research Areacancer
-
IndicationcMET Dysegulation Advanced Solid Tumors
Chemical Information
-
CAS Number1029714-89-3
-
Formula Weight412.42
-
Molecular FormulaC23H17FN6O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Liu X Wang Q Yang G et al. A Novel Kinase Inhibitor INCB28060 Blocks c-MET-Dependent Signaling Neoplastic Activities and Cross-Talk with EGFR and HER-3[J]. Clinical Cancer Research 2011 17(22):7127-7138.
molnova catalog
related products
-
Onartuzumab
Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.
-
BMS-817378
BMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
-
BMS-794833
BMS794833?is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM.
Cart
sales@molnova.com